Schedule 13D ownership disclosure

Mineralys Therapeutics Inc

Common Stock · CUSIP: 603170101

Event date: 2025-09-04

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Samsara BioCapital, L.P.Reported CIK 0001699737

    Shares: 5,674,916.00 · Class: 7.3%

  • Samsara BioCapital GP, LLCReported CIK 0001888829

    Shares: 5,674,916.00 · Class: 7.3%

  • Samsara Opportunity Fund, L.P.

    Shares: 588,235.00 · Class: 0.8%

  • Samsara Opportunity Fund GP, LLC

    Shares: 588,235.00 · Class: 0.8%

  • Srinivas AkkarajuReported CIK 0001253170

    Shares: 6,346,194.00 · Class: 8.2%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001415889-25-023916
Form type
SCHEDULE 13D/A
Filer
Mineralys Therapeutics, Inc.
CIK
CIK 1933414
Filed
Sep 08, 2025
Reporting period
Sep 04, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub